Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$10.27 and traded as high as C$11.90. Fennec Pharmaceuticals shares last traded at C$11.89, with a volume of 902 shares traded.
Fennec Pharmaceuticals Stock Up 1.7%
The company's 50-day simple moving average is C$10.27 and its two-hundred day simple moving average is C$9.30. The firm has a market capitalization of C$229.29 million, a P/E ratio of -201.41 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17.
Insider Buying and Selling
In other news, Director Jeffrey Hackman purchased 15,000 shares of the stock in a transaction on Monday, May 19th. The shares were acquired at an average price of C$9.77 per share, with a total value of C$146,580.00. Also, Director Rostislav Christov Raykov sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of C$10.66, for a total transaction of C$106,586.00. In the last ninety days, insiders sold 28,076 shares of company stock valued at $274,554. 16.20% of the stock is owned by corporate insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
